ROCKVILLE, Md., Aug. 7, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (the “Company”) announces the filing of a 510(k) premarket notification with the U.S. Food and Drug Administration (“FDA”) for clearance to market its AutoloGel(tm) Platelet Separation System for use in orthopedics. The application includes the option of mixing of platelet-rich plasma (“PRP”) derived by the AutoloGel(tm) System with autograft and/or allograft bone, intra-operatively, prior to application to an orthopedic site as deemed necessary by clinical use requirements.
